Tests whether lab-grown tumor tissue predicts osteosarcoma chemotherapy response
Studies whether lab-grown tumor cultures from biopsies can predict osteosarcoma response to chemotherapy.
Plain-language title generated from the registry record
Registry title: An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
Key facts
- Where
- Los Angeles, United StatesSee the site
Where in United States
- UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jonsson Comprehensive Cancer Center
- Trial code
- NCT06064682
- Record updated
- 11 May 2026
- Original description
The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.Read full original descriptionShow less
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma: PREMOST
The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.
Inclusion / exclusion criteria - Group1:; Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes; Inclusion / exclusion criteria - Group 2:; Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes.